Paolo Vitali, MD, PhD, FRCPC

Contact
paolo.vitali@mcgill.ca
6875 Boulevard Lasalle Montréal, QC H4H 1R3
Office:McGill University Research Centre for Studies in Aging
ORCID iD: https://orcid.org/0000-0001-8953-1542
Associated Resarcher, Douglas Research Centre
Assistant Professor, Department of Neurology & Neurosurgery, McGill University
Neurologist, Alzheimer Disease Research Unit, CIUSSS Ouest-de-‘Île-de-Montréal
Division: Clinical Research
Dr Paolo Vitali is a Faculty Lecturer at McGill University Department of Neurology and Neurosurgery, Faculty of Medicine. He is a board-certified neurologist (FRCPC) and registered neuropsychologist (Ordre des psychologues du Québec). He is staff neurologist at the CIUSSS Nord-de-l’Île-de-Montréal and associate neurologist at McGill University Research Centre for Studies in Aging.
Dr. Vitali is a board-certified neurologist and neuropsychologist. He is neurologist at the CIUSSS Ouest-de-l’Île-de-Montréal and at the McGill University Research Centre for Studies in Aging.
Dr. Vitali obtained a PhD in Clinical Psychology from University Vita-Salute San Raffaele, Italy, in 2004 and in Biomedical Sciences (Neuropsychology) from Université de Montréal in 2007. His research focus was on language disorders (aphasia) and cerebral plasticity following brain damage as measured by neuroimaging techniques. Since 2005, he has been a registered neuropsychologist with the Ordre des Psychologues du Québec. After graduating from the Medical School of Université Laval in 2010, he completed a residency program in Neurology at Université de Montréal and a PGY6 training in electromyography at McGill (2015). During his clinical training in neurology, he continued his research training. As part of his residency program he completed a two-month research fellowship at the Memory and Aging Center (UCSF-San Francisco) working on the identification of early-affected brain regions responsible for language deficits in atypical forms of dementia, and a six-month research rotation at the McGill University Research Centre for Studies in Aging working on the physiopathological mechanisms underlying dementia. His research training was funded by the FRQS in 2015. He has also collaborated in research studies funded by the Alzheimer’s Society, the Heart and Stroke Foundation, and the Canadian Institute of Health Research. Dr. Vitali is currently involved in the assessment and follow-up of patients presenting with neurodegenerative diseases, especially atypical dementia presenting with language impairments. He is an investigator in clinical trials for Alzheimer. He is also a clinical supervisor of PhD students in neuropsychology.
Areas of expertise:
Dementia, neuropsychology, aphasia, biomarkers
Publications
2025
Arslan, Burak; Brum, Wagner S; Pola, Ilaria; Therriault, Joseph; Rahmouni, Nesrine; Stevenson, Jenna; Servaes, Stijn; Tan, Kübra; Vitali, Paolo; Montembeault, Maxime; Klostranec, Jesse; Macedo, Arthur C; Tissot, Cecile; Gauthier, Serge; Lantero-Rodriguez, Juan; Zimmer, Eduardo R; Blennow, Kaj; Zetterberg, Henrik; Rosa-Neto, Pedro; Benedet, Andrea L; Ashton, Nicholas J
The impact of kidney function on Alzheimer's disease blood biomarkers: implications for predicting amyloid-β positivity Journal Article
In: Alzheimers Res Ther, vol. 17, no. 1, pp. 48, 2025, ISSN: 1758-9193.
@article{pmid39972340,
title = {The impact of kidney function on Alzheimer's disease blood biomarkers: implications for predicting amyloid-β positivity},
author = {Burak Arslan and Wagner S Brum and Ilaria Pola and Joseph Therriault and Nesrine Rahmouni and Jenna Stevenson and Stijn Servaes and Kübra Tan and Paolo Vitali and Maxime Montembeault and Jesse Klostranec and Arthur C Macedo and Cecile Tissot and Serge Gauthier and Juan Lantero-Rodriguez and Eduardo R Zimmer and Kaj Blennow and Henrik Zetterberg and Pedro Rosa-Neto and Andrea L Benedet and Nicholas J Ashton},
doi = {10.1186/s13195-025-01692-z},
issn = {1758-9193},
year = {2025},
date = {2025-02-01},
journal = {Alzheimers Res Ther},
volume = {17},
number = {1},
pages = {48},
abstract = {BACKGROUND: Impaired kidney function has a potential confounding effect on blood biomarker levels, including biomarkers for Alzheimer's disease (AD). Given the imminent use of certain blood biomarkers in the routine diagnostic work-up of patients with suspected AD, knowledge on the potential impact of comorbidities on the utility of blood biomarkers is important. We aimed to evaluate the association between kidney function, assessed through estimated glomerular filtration rate (eGFR) calculated from plasma creatinine and AD blood biomarkers, as well as their influence over predicting Aβ-positivity.nnMETHODS: We included 242 participants from the Translational Biomarkers in Aging and Dementia (TRIAD) cohort, comprising cognitively unimpaired individuals (CU; n = 124), mild cognitive impairment (MCI; n = 58), AD dementia (n = 34), and non-AD dementia (n = 26) patients all characterized by [F] AZD-4694. Plasma samples were analyzed for Aβ42, Aβ40, glial fibrillary acidic protein (GFAP), neurofilament light chain (NfL), tau phosphorylated at threonine 181 (p-tau181), 217 (p-tau217), 231 (p-tau231) and N-terminal containing tau fragments (NTA-tau) using Simoa technology. Kidney function was assessed by eGFR in mL/min/1.73 m, based on plasma creatinine levels, age, and sex. Participants were also stratified according to their eGFR-indexed stages of chronic kidney disease (CKD). We evaluated the association between eGFR and blood biomarker levels with linear models and assessed whether eGFR provided added predictive value to determine Aβ-positivity with logistic regression models.nnRESULTS: Biomarker concentrations were highest in individuals with CKD stage 3, followed by stages 2 and 1, but differences were only significant for NfL, Aβ42, and Aβ40 (not Aβ42/Aβ40). All investigated biomarkers showed significant associations with eGFR except plasma NTA-tau, with stronger relationships observed for Aβ40 and NfL. However, after adjusting for either age, sex or Aβ-PET SUVr, the association with eGFR was no longer significant for all biomarkers except Aβ40, Aβ42, NfL, and GFAP. When evaluating whether accounting for kidney function could lead to improved prediction of Aβ-positivity, we observed no improvements in model fit (Akaike Information Criterion, AIC) or in discriminative performance (AUC) by adding eGFR to a base model including each plasma biomarker, age, and sex. While covariates like age and sex improved model fit, eGFR contributed minimally, and there were no significant differences in clinical discrimination based on AUC values.nnCONCLUSIONS: We found that kidney function seems to be associated with AD blood biomarker concentrations. However, these associations did not remain significant after adjusting for age and sex, except for Aβ40, Aβ42, NfL, and GFAP. While covariates such as age and sex improved prediction of Aβ-positivity, including eGFR in the models did not lead to improved prediction for any biomarker. Our findings indicate that renal function, within the normal to mild impairment range, does not seem to have a clinically relevant impact when using highly accurate blood biomarkers, such as p-tau217, in a biomarker-supported diagnosis.},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
Aumont, Etienne; Bedard, Marc-André; Bussy, Aurélie; Arias, Jaime Fernandez; Tissot, Cecile; Hall, Brandon J; Therriault, Joseph; Rahmouni, Nesrine; Stevenson, Jenna; Servaes, Stijn; Macedo, Arthur C; Vitali, Paolo; Poltronetti, Nina Margherita; Fliaguine, Olga; Trudel, Lydia; Gauthier, Serge; Chakravarty, Mallar M; Rosa-Neto, Pedro
Hippocampal atrophy over two years in relation to tau, amyloid-β and memory in older adults Journal Article
In: Neurobiol Aging, vol. 146, pp. 48–57, 2025, ISSN: 1558-1497.
@article{pmid39631245,
title = {Hippocampal atrophy over two years in relation to tau, amyloid-β and memory in older adults},
author = {Etienne Aumont and Marc-André Bedard and Aurélie Bussy and Jaime Fernandez Arias and Cecile Tissot and Brandon J Hall and Joseph Therriault and Nesrine Rahmouni and Jenna Stevenson and Stijn Servaes and Arthur C Macedo and Paolo Vitali and Nina Margherita Poltronetti and Olga Fliaguine and Lydia Trudel and Serge Gauthier and Mallar M Chakravarty and Pedro Rosa-Neto},
doi = {10.1016/j.neurobiolaging.2024.11.007},
issn = {1558-1497},
year = {2025},
date = {2025-02-01},
journal = {Neurobiol Aging},
volume = {146},
pages = {48--57},
abstract = {In this longitudinal brain imaging study, we aimed to characterize hippocampal tau accumulation and subfield atrophy relative to cortical amyloid-β and memory performance. We measured tau-PET in regions associated with Braak stages I to VI, global amyloid-PET burden, hippocampal subfield volumes and memory assessments from 173 participants aged 55-85. Eighty-six of these participants were tested again two years later. Tau-PET change in the Braak II region, corresponding to the hippocampus and the entorhinal cortex, was significantly associated with the cornu ammonis 1 (CA1) atrophy and memory score. This CA1 atrophy did not significantly mediate the association between tau and memory, nor did global amyloid-PET burden correlate with tau-PET changes in the Braak II region. Longitudinal hippocampal tau accumulation is amyloid-β-independent and co-localized with subfield atrophy. As tau-associated memory decline seems to be independent from hippocampal atrophy, other mechanisms could contribute to the deficit.},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
Arias, Jaime Fernández; Brum, Wagner S; Salvadó, Gemma; Therriault, Joseph; Servaes, Stijn; Wang, Yi-Ting; Aumont, Etienne; Rahmouni, Nesrine; Macedo, Arthur; Quispialaya, Kely; Hosseini, Seyyed Ali; Kunach, Peter; Jia, Wan Lu; Chan, Tevy; Trudel, Lydia; Hall, Brandon; Zheng, Yanseng; Mohapatra, Sejal; Mathotaarachchi, Sulantha S; Vitali, Paolo; Tissot, Cécile; Bezgin, Gleb; Iturria-Medina, Yasser; Ashton, Nicholas J; Benedet, Andréa Lessa; Karikari, Thomas K; Triana-Baltzer, Gallen; Klostranec, Jesse; Kolb, Hartmuth C; Zimmer, Eduardo R; Janelidze, Shorena; Mattson-Carlgren, Niklas; Stomrud, Erik; Palmqvist, Sebastian; Zetterberg, Henrik; Blennow, Kaj; Pascoal, Tharick; Montembeault, Maxime; Hansson, Oskar; Rosa-Neto, Pedro
Plasma phosphorylated tau217 strongly associates with memory deficits in the Alzheimer's disease spectrum Journal Article
In: Brain, 2025, ISSN: 1460-2156.
@article{pmid39879633,
title = {Plasma phosphorylated tau217 strongly associates with memory deficits in the Alzheimer's disease spectrum},
author = {Jaime Fernández Arias and Wagner S Brum and Gemma Salvadó and Joseph Therriault and Stijn Servaes and Yi-Ting Wang and Etienne Aumont and Nesrine Rahmouni and Arthur Macedo and Kely Quispialaya and Seyyed Ali Hosseini and Peter Kunach and Wan Lu Jia and Tevy Chan and Lydia Trudel and Brandon Hall and Yanseng Zheng and Sejal Mohapatra and Sulantha S Mathotaarachchi and Paolo Vitali and Cécile Tissot and Gleb Bezgin and Yasser Iturria-Medina and Nicholas J Ashton and Andréa Lessa Benedet and Thomas K Karikari and Gallen Triana-Baltzer and Jesse Klostranec and Hartmuth C Kolb and Eduardo R Zimmer and Shorena Janelidze and Niklas Mattson-Carlgren and Erik Stomrud and Sebastian Palmqvist and Henrik Zetterberg and Kaj Blennow and Tharick Pascoal and Maxime Montembeault and Oskar Hansson and Pedro Rosa-Neto},
doi = {10.1093/brain/awaf033},
issn = {1460-2156},
year = {2025},
date = {2025-01-01},
journal = {Brain},
abstract = {Plasma phosphorylated tau biomarkers open unprecedented opportunities for identifying carriers of Alzheimer's disease pathophysiology in early disease stages using minimally invasive techniques. Plasma p-tau biomarkers are believed to reflect tau phosphorylation and secretion. However, it remains unclear to what extent the magnitude of plasma p-tau abnormalities reflects neuronal network disturbance in the form of cognitive impairment. To address this question, we included 103 cognitively unimpaired elderly and 40 cognitively impaired, amyloid-β positive individuals from the TRIAD cohort, as well as 336 cognitively unimpaired and 216 cognitively impaired, amyloid-β positive older adults from the BioFINDER-2 cohort. Participants had tau PET scans, amyloid PET scans or amyloid CSF, p-tau217, p-tau181 and p-tau231 blood measures, structural T1-MRI and cognitive assessments. In this cross-sectional study, we used regression models and correlation analyses to assess the relationship between plasma biomarkers and cognitive scores. Furthermore, we applied receiver operating characteristic curves to assess cognitive impairment across plasma biomarkers. Finally, we categorized participants into amyloid (A), p-tau (T1), and tau PET (T2) positive (+) or negative (-) profiles and ran nonparametric comparisons to assess differences across cognitive domains. We found that plasma p-tau217 was more associated with cognitive performance than p-tau181 and p-tau231, and that this relationship was particularly strong for memory scores (TRIAD: βp-tau217=-0.53; βp-tau181=-0.35; βp-tau231=-0.24; BioFINDER-2: βp-tau217=-0.52; βp-tau181=-0.24; βp-tau231=-0.29). Associations in amyloid-β positive participants resembled these results, but other cognitive scores also showed strong associations in cognitively impaired individuals. Moreover, plasma p-tau217 outperformed plasma p-tau181 and plasma p-tau231 in identifying memory impairment (Area Under the Curve values for TRIAD: p-tau217=0.86, p-tau181=0.77, p-tau231=0.75; Area Under the Curve values for BioFINDER-2: p-tau217=0.86, p-tau181=0.76, p-tau231=0.81), and in identifying executive function impairment only in the BioFINDER-2 cohort (p-tau217=0.82, p-tau181=0.76, p-tau231=0.76). Lastly, we showed that subtle memory deficits were present in A+T1+T2- participants for plasma p-tau217 (p=0.007) and plasma p-tau181 (p=0.01) in the TRIAD cohort, and for all biomarkers across cognitive domains in A+T1-T2- and A+T1+T2- individuals (p<0.001 in all) in the BioFINDER-2 cohort. A+T1+T2+ individuals showed cognitive deficits in both cohorts (p<0.001 in all). Together, our results suggest that plasma p-tau217 stands out as a biomarker capable of identifying memory deficits due to Alzheimer's disease and that memory impairment certainly occurs in amyloid and plasma p-tau positive individuals that have no significant amounts of tau in the neocortex.},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
2024
Macedo, Arthur C; Therriault, Joseph; Tissot, Cécile; Aumont, Étienne; Servaes, Stijn; Rahmouni, Nesrine; Fernandez-Arias, Jaime; Lussier, Firoza Z; Wang, Yi-Ting; Ng, Kok Pin; Vermeiren, Marie; Bezgin, Gleb; Socualaya, Kely Quispialaya; Stevenson, Jenna; Hosseini, Seyyed Ali; Chamoun, Mira; Ferrari-Souza, João Pedro; Ferreira, Pâmela C L; Bellaver, Bruna; Leffa, Douglas Teixeira; Vitali, Paolo; Zimmer, Eduardo R; Ismail, Zahinoor; Pascoal, Tharick A; Gauthier, Serge; Rosa-Neto, Pedro
Modeling the progression of neuropsychiatric symptoms in Alzheimer's disease with PET-based Braak staging Journal Article
In: Neurobiol Aging, vol. 144, pp. 127–137, 2024, ISSN: 1558-1497.
@article{pmid39326302,
title = {Modeling the progression of neuropsychiatric symptoms in Alzheimer's disease with PET-based Braak staging},
author = {Arthur C Macedo and Joseph Therriault and Cécile Tissot and Étienne Aumont and Stijn Servaes and Nesrine Rahmouni and Jaime Fernandez-Arias and Firoza Z Lussier and Yi-Ting Wang and Kok Pin Ng and Marie Vermeiren and Gleb Bezgin and Kely Quispialaya Socualaya and Jenna Stevenson and Seyyed Ali Hosseini and Mira Chamoun and João Pedro Ferrari-Souza and Pâmela C L Ferreira and Bruna Bellaver and Douglas Teixeira Leffa and Paolo Vitali and Eduardo R Zimmer and Zahinoor Ismail and Tharick A Pascoal and Serge Gauthier and Pedro Rosa-Neto},
doi = {10.1016/j.neurobiolaging.2024.09.009},
issn = {1558-1497},
year = {2024},
date = {2024-12-01},
journal = {Neurobiol Aging},
volume = {144},
pages = {127--137},
abstract = {In Alzheimer's disease (AD), neuropsychiatric symptoms (NPS) correlate with tau deposition in the brain. Here, we investigated the association of PET-based Braak stages with NPS and assessed whether they predict annual changes in NPS. We evaluated 231 individuals in the aging and AD continuum. Participants were assigned a Braak stage at baseline and followed for 1.97 (s.d. 0.62) years. NPS were investigated using the Mild Behavioral Impairment Checklist (MBI-C) and the Neuropsychiatric Inventory Questionnaire severity (NPI-Q-S) and distress (NPI-Q-D) scales. Multiple linear regressions (MLR) assessed the association of Braak stages with baseline NPS and the annual change in NPS scores. At baseline, stages I-II, III-IV, and V-VI were associated with higher MBI-C, NPI-Q-S, and NPI-Q-D scores. Stages V-VI were associated with a significant annual increase in MBI-C scores. These findings suggest that tau accumulation may manifest clinically with an increase in NPS, which seems to be an early event in AD pathophysiology. Moreover, PET-based Braak staging appears to be a good predictor of NPS severity progression.},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
Dupuy, Emma Gabrielle; Besnier, Florent; Gagnon, Christine; Vincent, Thomas; Vrinceanu, Tudor; Blanchette, Caroll-Ann; Gervais, Jeremy; Breton, Juliana; Saillant, Kathia; Iglesies-Grau, Josep; Belleville, Sylvie; Juneau, Martin; Vitali, Paolo; Nigam, Anil; Gayda, Mathieu; Bherer, Louis
In: Exp Gerontol, vol. 198, pp. 112628, 2024, ISSN: 1873-6815.
@article{pmid39505286,
title = {Effects of home-based exercise alone or combined with cognitive training on cognition in community-dwelling older adults: A randomized clinical trial},
author = {Emma Gabrielle Dupuy and Florent Besnier and Christine Gagnon and Thomas Vincent and Tudor Vrinceanu and Caroll-Ann Blanchette and Jeremy Gervais and Juliana Breton and Kathia Saillant and Josep Iglesies-Grau and Sylvie Belleville and Martin Juneau and Paolo Vitali and Anil Nigam and Mathieu Gayda and Louis Bherer},
doi = {10.1016/j.exger.2024.112628},
issn = {1873-6815},
year = {2024},
date = {2024-12-01},
journal = {Exp Gerontol},
volume = {198},
pages = {112628},
abstract = {BACKGROUND: Structured and supervised physical exercise and cognitive training are two efficient ways to enhance cognition in older adults. Performing both within a combined intervention could maximize their effect on cognition due to their potential synergy on brain functions. During the COVID-19 pandemic, these interventions were particularly relevant due to the collateral impact of social restrictions regarding physical activity and the level of cognitive stimulation. However, the benefits of remotely monitored intervention combining physical exercise and cognitive training for older adult cognition remain to be demonstrated.nnMETHODS: 127 older adults (age: 65.20 ± 7.95) were randomized in two arms, encouraging self-engagement in six months of home-based physical exercise alone or combined with cognitive training, monitored by phone once a week. Neuropsychological assessment was performed under videoconference supervision at baseline and after three and six months. Composite Z-scores were calculated for processing speed, executive functioning, working, and episodic memory to assess changes after three and six months of training. The weekly metabolic expenditure of self-reported activities was estimated using the compendium of physical activity to distinguish participants performing higher and lower doses of exercise (median split).nnRESULTS: 106 participants (83.46 %) completed the 6-month training. Results showed a greater Z-score change in executive functioning for participants in the combined arm than those who only exercised (F = 4.127, p = 0.046, η = 0.050). Group x Exercise dose interaction was observed for episodic memory Z-score change (F = 6.736, p = 0.011, η = 0.070), with a greater improvement for participants performing higher doses of exercise compared to those who performed a lower dose, only in exercise alone arm. Performing a higher dose of exercise increased the working memory Z-score change in both intervention arms compared to a lower dose (F = 7.391, p = 0.008, η = 0.076).nnCONCLUSION: Remote combined training may lead to larger improvement in executive functioning than exercise alone. Physical exercise showed a dose-related improvement in working and episodic memory performances. The combination of cognitive interventions mitigated the effects of exercise on episodic memory. These results suggest that home-based exercise and cognitive training may help improve older adults' cognition.nnTRIAL REGISTRATION: COVEPIC was retrospectively registered on December 03, 2020.nnCLINICAL TRIALS IDENTIFIER: NCT04635462 - https://clinicaltrials.gov/ct2/show/record/NCT04635462?term=NCT04635462&draw=2&rank=1.},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
Therriault, Joseph; Janelidze, Shorena; Benedet, Andréa Lessa; Ashton, Nicholas J; Martínez, Javier Arranz; Gonzalez-Escalante, Armand; Bellaver, Bruna; Alcolea, Daniel; Vrillon, Agathe; Karim, Helmet; Mielke, Michelle M; Hong, Chang Hyung; Roh, Hyun Woong; Contador, José; Pijoan, Albert Puig; Algeciras-Schimnich, Alicia; Vemuri, Prashanthi; Graff-Radford, Jonathan; Lowe, Val J; Karikari, Thomas K; Jonaitis, Erin; Brum, Wagner; Tissot, Cécile; Servaes, Stijn; Rahmouni, Nesrine; Macedo, Arthur C; Stevenson, Jenna; Fernandez-Arias, Jaime; Wang, Yi-Ting; Woo, Marcel S; Friese, Manuel A; Jia, Wan Lu; Dumurgier, Julien; Hourregue, Claire; Cognat, Emmanuel; Ferreira, Pamela Lukasewicz; Vitali, Paolo; Johnson, Sterling; Pascoal, Tharick A; Gauthier, Serge; Lleó, Alberto; Paquet, Claire; Petersen, Ronald C; Salmon, David; Mattsson-Carlgren, Niklas; Palmqvist, Sebastian; Stomrud, Erik; Galasko, Douglas; Son, Sang Joon; Zetterberg, Henrik; Fortea, Juan; Suárez-Calvet, Marc; Jack, Clifford R; Blennow, Kaj; Hansson, Oskar; Rosa-Neto, Pedro
Diagnosis of Alzheimer's disease using plasma biomarkers adjusted to clinical probability Journal Article
In: Nat Aging, vol. 4, no. 11, pp. 1529–1537, 2024, ISSN: 2662-8465.
@article{pmid39533113,
title = {Diagnosis of Alzheimer's disease using plasma biomarkers adjusted to clinical probability},
author = {Joseph Therriault and Shorena Janelidze and Andréa Lessa Benedet and Nicholas J Ashton and Javier Arranz Martínez and Armand Gonzalez-Escalante and Bruna Bellaver and Daniel Alcolea and Agathe Vrillon and Helmet Karim and Michelle M Mielke and Chang Hyung Hong and Hyun Woong Roh and José Contador and Albert Puig Pijoan and Alicia Algeciras-Schimnich and Prashanthi Vemuri and Jonathan Graff-Radford and Val J Lowe and Thomas K Karikari and Erin Jonaitis and Wagner Brum and Cécile Tissot and Stijn Servaes and Nesrine Rahmouni and Arthur C Macedo and Jenna Stevenson and Jaime Fernandez-Arias and Yi-Ting Wang and Marcel S Woo and Manuel A Friese and Wan Lu Jia and Julien Dumurgier and Claire Hourregue and Emmanuel Cognat and Pamela Lukasewicz Ferreira and Paolo Vitali and Sterling Johnson and Tharick A Pascoal and Serge Gauthier and Alberto Lleó and Claire Paquet and Ronald C Petersen and David Salmon and Niklas Mattsson-Carlgren and Sebastian Palmqvist and Erik Stomrud and Douglas Galasko and Sang Joon Son and Henrik Zetterberg and Juan Fortea and Marc Suárez-Calvet and Clifford R Jack and Kaj Blennow and Oskar Hansson and Pedro Rosa-Neto},
doi = {10.1038/s43587-024-00731-y},
issn = {2662-8465},
year = {2024},
date = {2024-11-01},
journal = {Nat Aging},
volume = {4},
number = {11},
pages = {1529--1537},
abstract = {Recently approved anti-amyloid immunotherapies for Alzheimer's disease (AD) require evidence of amyloid-β pathology from positron emission tomography (PET) or cerebrospinal fluid (CSF) before initiating treatment. Blood-based biomarkers promise to reduce the need for PET or CSF testing; however, their interpretation at the individual level and the circumstances requiring confirmatory testing are poorly understood. Individual-level interpretation of diagnostic test results requires knowledge of disease prevalence in relation to clinical presentation (clinical pretest probability). Here, in a study of 6,896 individuals evaluated from 11 cohort studies from six countries, we determined the positive and negative predictive value of five plasma biomarkers for amyloid-β pathology in cognitively impaired individuals in relation to clinical pretest probability. We observed that p-tau217 could rule in amyloid-β pathology in individuals with probable AD dementia (positive predictive value above 95%). In mild cognitive impairment, p-tau217 interpretation depended on patient age. Negative p-tau217 results could rule out amyloid-β pathology in individuals with non-AD dementia syndromes (negative predictive value between 90% and 99%). Our findings provide a framework for the individual-level interpretation of plasma biomarkers, suggesting that p-tau217 combined with clinical phenotyping can identify patients where amyloid-β pathology can be ruled in or out without the need for PET or CSF confirmatory testing.},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
Macedo, Arthur C; Therriault, Joseph; Tissot, Cécile; Fernandez-Arias, Jaime; Ferreira, Pamela C L; Vitali, Paolo; Servaes, Stijn; Rahmouni, Nesrine; Vermeiren, Marie; Bezgin, Gleb; Lussier, Firoza Z; Stevenson, Jenna; Wang, Yi-Ting; Socualaya, Kely Quispialaya; Kunach, Peter; Nazneen, Tahnia; Hosseini, Seyyed Ali; Pallen, Vanessa; Stevenson, Alyssa; Ferrari-Souza, João Pedro; Bellaver, Bruna; Leffa, Douglas Teixeira; Ng, Kok Pin; Zimmer, Eduardo R; Pascoal, Tharick A; Gauthier, Serge; Rosa-Neto, Pedro
Predicting functional decline in aging and Alzheimer's disease with PET-based Braak staging Journal Article
In: Brain Commun, vol. 6, no. 2, pp. fcae043, 2024, ISSN: 2632-1297.
@article{pmid38482373,
title = {Predicting functional decline in aging and Alzheimer's disease with PET-based Braak staging},
author = {Arthur C Macedo and Joseph Therriault and Cécile Tissot and Jaime Fernandez-Arias and Pamela C L Ferreira and Paolo Vitali and Stijn Servaes and Nesrine Rahmouni and Marie Vermeiren and Gleb Bezgin and Firoza Z Lussier and Jenna Stevenson and Yi-Ting Wang and Kely Quispialaya Socualaya and Peter Kunach and Tahnia Nazneen and Seyyed Ali Hosseini and Vanessa Pallen and Alyssa Stevenson and João Pedro Ferrari-Souza and Bruna Bellaver and Douglas Teixeira Leffa and Kok Pin Ng and Eduardo R Zimmer and Tharick A Pascoal and Serge Gauthier and Pedro Rosa-Neto},
doi = {10.1093/braincomms/fcae043},
issn = {2632-1297},
year = {2024},
date = {2024-01-01},
journal = {Brain Commun},
volume = {6},
number = {2},
pages = {fcae043},
abstract = {The progression of PET-based Braak stages correlates with cognitive deterioration in aging and Alzheimer's disease. Here, we investigate the association between PET-based Braak stages and functional impairment and assess whether PET-based Braak staging predicts a longitudinal decline in the performance of activities of daily living. In this cohort study, we evaluated cognitively unimpaired individuals and individuals with mild cognitive impairment or Alzheimer's disease dementia. Participants underwent [F]MK6240 tau-PET, were assigned a PET-based Braak stage at baseline and were followed for a mean (SD) of 1.97 (0.66) years. Functional performance was evaluated with the Functional Activities Questionnaire, Everyday Cognition and functional Clinical Dementia Rating sum of boxes. Multiple linear regressions assessed the association of PET-based Braak stages with baseline functionality and with the longitudinal rate of change in functional scores, adjusting for age, sex and amyloid-β load. We employed voxel-based regression models to investigate the association between functionality and tau-PET signal and assessed the voxel overlap with Braak regions of interest. We included 291 individuals (181 cognitively unimpaired, 56 amyloid-β+ mild cognitive impairment and 54 amyloid-β+ Alzheimer's disease) aged 70.60 (7.48) years. At baseline, PET-based Braak stages III-IV ( = 0.43, = 0.03) and V-VI ( = 1.20, < 0.0001) showed associations with poorer Functional Activities Questionnaire scores. Similarly, stages III-IV ( = 0.43, = 0.02) and V-VI ( = 1.15, < 0.0001) were associated with worse Everyday Cognition scores. Only stages V-VI were associated with higher functional Clinical Dementia Rating sum of boxes ( = 1.17, < 0.0001) scores. Increased tau-PET signals in all Braak regions of interest were linked to worse performance in all tools. The voxelwise analysis showed widespread cortical associations between functional impairment and tau-PET and high voxel overlap with Braak regions of interest. Baseline PET-based Braak stages V-VI predicted significant longitudinal functional decline as assessed by the Functional Activities Questionnaire ( = 1.69, < 0.0001), the Everyday Cognition ( = 1.05, = 0.001) and the functional Clinical Dementia Rating sum of boxes ( = 1.29, < 0.0001). Our results suggest that functional impairment increases with the severity of tau accumulation. These findings also indicate that PET-based Braak staging is a good predictor of functional impairment in the Alzheimer's disease continuum. Finally, our study provides evidence for the clinical significance of the PET-based Braak staging framework.},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
Therriault, Joseph; Woo, Marcel S; Salvadó, Gemma; Gobom, Johan; Karikari, Thomas K; Janelidze, Shorena; Servaes, Stijn; Rahmouni, Nesrine; Tissot, Cécile; Ashton, Nicholas J; Benedet, Andréa Lessa; Montoliu-Gaya, Laia; Macedo, Arthur C; Lussier, Firoza Z; Stevenson, Jenna; Vitali, Paolo; Friese, Manuel A; Massarweh, Gassan; Soucy, Jean-Paul; Pascoal, Tharick A; Stomrud, Erik; Palmqvist, Sebastian; Mattsson-Carlgren, Niklas; Gauthier, Serge; Zetterberg, Henrik; Hansson, Oskar; Blennow, Kaj; Rosa-Neto, Pedro
Comparison of immunoassay- with mass spectrometry-derived p-tau quantification for the detection of Alzheimer's disease pathology Journal Article
In: Mol Neurodegener, vol. 19, no. 1, pp. 2, 2024, ISSN: 1750-1326.
@article{pmid38185677,
title = {Comparison of immunoassay- with mass spectrometry-derived p-tau quantification for the detection of Alzheimer's disease pathology},
author = {Joseph Therriault and Marcel S Woo and Gemma Salvadó and Johan Gobom and Thomas K Karikari and Shorena Janelidze and Stijn Servaes and Nesrine Rahmouni and Cécile Tissot and Nicholas J Ashton and Andréa Lessa Benedet and Laia Montoliu-Gaya and Arthur C Macedo and Firoza Z Lussier and Jenna Stevenson and Paolo Vitali and Manuel A Friese and Gassan Massarweh and Jean-Paul Soucy and Tharick A Pascoal and Erik Stomrud and Sebastian Palmqvist and Niklas Mattsson-Carlgren and Serge Gauthier and Henrik Zetterberg and Oskar Hansson and Kaj Blennow and Pedro Rosa-Neto},
doi = {10.1186/s13024-023-00689-2},
issn = {1750-1326},
year = {2024},
date = {2024-01-01},
journal = {Mol Neurodegener},
volume = {19},
number = {1},
pages = {2},
abstract = {BACKGROUND: Antibody-based immunoassays have enabled quantification of very low concentrations of phosphorylated tau (p-tau) protein forms in cerebrospinal fluid (CSF), aiding in the diagnosis of AD. Mass spectrometry enables absolute quantification of multiple p-tau variants within a single run. The goal of this study was to compare the performance of mass spectrometry assessments of p-tau, p-tau and p-tau with established immunoassay techniques.nnMETHODS: We measured p-tau, p-tau and p-tau concentrations in CSF from 173 participants from the TRIAD cohort and 394 participants from the BioFINDER-2 cohort using both mass spectrometry and immunoassay methods. All subjects were clinically evaluated by dementia specialists and had amyloid-PET and tau-PET assessments. Bland-Altman analyses evaluated the agreement between immunoassay and mass spectrometry p-tau, p-tau and p-tau. P-tau associations with amyloid-PET and tau-PET uptake were also compared. Receiver Operating Characteristic (ROC) analyses compared the performance of mass spectrometry and immunoassays p-tau concentrations to identify amyloid-PET positivity.nnRESULTS: Mass spectrometry and immunoassays of p-tau were highly comparable in terms of diagnostic performance, between-group effect sizes and associations with PET biomarkers. In contrast, p-tau and p-tau concentrations measured using antibody-free mass spectrometry had lower performance compared with immunoassays.nnCONCLUSIONS: Our results suggest that while similar overall, immunoassay-based p-tau biomarkers are slightly superior to antibody-free mass spectrometry-based p-tau biomarkers. Future work is needed to determine whether the potential to evaluate multiple biomarkers within a single run offsets the slightly lower performance of antibody-free mass spectrometry-based p-tau quantification.},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
2023
Therriault, Joseph; Servaes, Stijn; Tissot, Cécile; Rahmouni, Nesrine; Ashton, Nicholas J; Benedet, Andréa Lessa; Karikari, Thomas K; Macedo, Arthur C; Lussier, Firoza Z; Stevenson, Jenna; Wang, Yi-Ting; Fernandez-Arias, Jaime; Stevenson, Alyssa; Socualaya, Kely Quispialaya; Haeger, Arlette; Nazneen, Tahnia; Aumont, Étienne; Hosseini, Ali; Rej, Soham; Vitali, Paolo; Triana-Baltzer, Gallen; Kolb, Hartmuth C; Soucy, Jean-Paul; Pascoal, Tharick A; Gauthier, Serge; Zetterberg, Henrik; Blennow, Kaj; Rosa-Neto, Pedro
Equivalence of plasma p-tau217 with cerebrospinal fluid in the diagnosis of Alzheimer's disease Journal Article
In: Alzheimers Dement, 2023, ISSN: 1552-5279.
@article{pmid37078495,
title = {Equivalence of plasma p-tau217 with cerebrospinal fluid in the diagnosis of Alzheimer's disease},
author = {Joseph Therriault and Stijn Servaes and Cécile Tissot and Nesrine Rahmouni and Nicholas J Ashton and Andréa Lessa Benedet and Thomas K Karikari and Arthur C Macedo and Firoza Z Lussier and Jenna Stevenson and Yi-Ting Wang and Jaime Fernandez-Arias and Alyssa Stevenson and Kely Quispialaya Socualaya and Arlette Haeger and Tahnia Nazneen and Étienne Aumont and Ali Hosseini and Soham Rej and Paolo Vitali and Gallen Triana-Baltzer and Hartmuth C Kolb and Jean-Paul Soucy and Tharick A Pascoal and Serge Gauthier and Henrik Zetterberg and Kaj Blennow and Pedro Rosa-Neto},
doi = {10.1002/alz.13026},
issn = {1552-5279},
year = {2023},
date = {2023-04-01},
journal = {Alzheimers Dement},
abstract = {INTRODUCTION: Plasma biomarkers are promising tools for Alzheimer's disease (AD) diagnosis, but comparisons with more established biomarkers are needed.nnMETHODS: We assessed the diagnostic performance of p-tau , p-tau , and p-tau in plasma and CSF in 174 individuals evaluated by dementia specialists and assessed with amyloid-PET and tau-PET. Receiver operating characteristic (ROC) analyses assessed the performance of plasma and CSF biomarkers to identify amyloid-PET and tau-PET positivity.nnRESULTS: Plasma p-tau biomarkers had lower dynamic ranges and effect sizes compared to CSF p-tau. Plasma p-tau (AUC = 76%) and p-tau (AUC = 82%) assessments performed inferior to CSF p-tau (AUC = 87%) and p-tau (AUC = 95%) for amyloid-PET positivity. However, plasma p-tau (AUC = 91%) had diagnostic performance indistinguishable from CSF (AUC = 94%) for amyloid-PET positivity.nnDISCUSSION: Plasma and CSF p-tau had equivalent diagnostic performance for biomarker-defined AD. Our results suggest that plasma p-tau may help reduce the need for invasive lumbar punctures without compromising accuracy in the identification of AD.nnHIGHLIGHTS: p-tau in plasma performed equivalent to p-tau in CSF for the diagnosis of AD, suggesting the increased accessibility of plasma p-tau is not offset by lower accuracy. p-tau biomarkers in plasma had lower mean fold-changes between amyloid-PET negative and positive groups than p-tau biomarkers in CSF. CSF p-tau biomarkers had greater effect sizes than plasma p-tau biomarkers when differentiating between amyloid-PET positive and negative groups. Plasma p-tau and plasma p-tau performed worse than p-tau and p-tau in CSF for AD diagnosis.},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
Arias, Jaime Fernández; Therriault, Joseph; Thomas, Emilie; Lussier, Firoza Z; Bezgin, Gleb; Tissot, Cécile; Servaes, Stijn; Mathotaarachchi, Sulantha S; Schoemaker, Dorothée; Stevenson, Jenna; Rahmouni, Nesrine; Kang, Min Su; Pallen, Vanessa; Poltronetti, Nina Margherita; Wang, Yi-Ting; Kunach, Peter; Chamoun, Mira; S, Kely M Quispialaya; Vitali, Paolo; Massarweh, Gassan; Gauthier, Serge; Rajah, Maria N; Pascoal, Tharick; Rosa-Neto, Pedro
Verbal memory formation across PET-based Braak stages of tau accumulation in Alzheimer's disease Journal Article
In: Brain Commun, vol. 5, no. 3, pp. fcad146, 2023, ISSN: 2632-1297.
@article{pmid37252014,
title = {Verbal memory formation across PET-based Braak stages of tau accumulation in Alzheimer's disease},
author = {Jaime Fernández Arias and Joseph Therriault and Emilie Thomas and Firoza Z Lussier and Gleb Bezgin and Cécile Tissot and Stijn Servaes and Sulantha S Mathotaarachchi and Dorothée Schoemaker and Jenna Stevenson and Nesrine Rahmouni and Min Su Kang and Vanessa Pallen and Nina Margherita Poltronetti and Yi-Ting Wang and Peter Kunach and Mira Chamoun and Kely M Quispialaya S and Paolo Vitali and Gassan Massarweh and Serge Gauthier and Maria N Rajah and Tharick Pascoal and Pedro Rosa-Neto},
doi = {10.1093/braincomms/fcad146},
issn = {2632-1297},
year = {2023},
date = {2023-01-01},
journal = {Brain Commun},
volume = {5},
number = {3},
pages = {fcad146},
abstract = {A classical early sign of typical Alzheimer's disease is memory decline, which has been linked to the aggregation of tau in the medial temporal lobe. Verbal delayed free recall and recognition tests have consistently probed useful to detect early memory decline, and there is substantial debate on how performance, particularly in recognition tests, is differentially affected through health and disease in older adults. Using PET-Braak staging, we investigated delayed recall and recognition memory dysfunction across the Alzheimer's disease spectrum. Our cross-sectional study included 144 cognitively unimpaired elderly, 39 amyloid-β+ individuals with mild cognitive impairment and 29 amyloid-β+ Alzheimer's disease patients from the Translational Biomarkers in Aging and Dementia cohort, who underwent [F]MK6240 tau and [F]AZD4694 amyloid PET imaging, structural MRI and memory assessments. We applied non-parametric comparisons, correlation analyses, regression models and voxel-wise analyses. In comparison with PET-Braak Stage 0, we found that reduced, but not clinically significant, delayed recall starts at PET-Braak Stage II (adjusted < 0.0015), and that recognition (adjusted = 0.011) displayed a significant decline starting at PET-Braak Stage IV. While performance in both delayed recall and recognition related to tau in nearly the same cortical areas, further analyses showed that delayed recall rendered stronger associations in areas of early tau accumulation, whereas recognition displayed stronger correlations in mostly posterior neocortical regions. Our results support the notion that delayed recall and recognition deficits are predominantly associated with tau load in allocortical and neocortical areas, respectively. Overall, delayed recall seems to be more dependent on the integrity of anterior medial temporal lobe structures, while recognition appears to be more affected by tau accumulation in cortices beyond medial temporal regions.},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
Aumont, Etienne; Bussy, Aurélie; Bedard, Marc-André; Bezgin, Gleb; Therriault, Joseph; Savard, Melissa; Arias, Jaime Fernandez; Sziklas, Viviane; Vitali, Paolo; Poltronetti, Nina Margherita; Pallen, Vanessa; Thomas, Emilie; Gauthier, Serge; Kobayashi, Eliane; Rahmouni, Nesrine; Stevenson, Jenna; Tissot, Cecile; Chakravarty, Mallar M; Rosa-Neto, Pedro
Hippocampal subfield associations with memory depend on stimulus modality and retrieval mode Journal Article
In: Brain Commun, vol. 5, no. 6, pp. fcad309, 2023, ISSN: 2632-1297.
@article{pmid38035364,
title = {Hippocampal subfield associations with memory depend on stimulus modality and retrieval mode},
author = {Etienne Aumont and Aurélie Bussy and Marc-André Bedard and Gleb Bezgin and Joseph Therriault and Melissa Savard and Jaime Fernandez Arias and Viviane Sziklas and Paolo Vitali and Nina Margherita Poltronetti and Vanessa Pallen and Emilie Thomas and Serge Gauthier and Eliane Kobayashi and Nesrine Rahmouni and Jenna Stevenson and Cecile Tissot and Mallar M Chakravarty and Pedro Rosa-Neto},
doi = {10.1093/braincomms/fcad309},
issn = {2632-1297},
year = {2023},
date = {2023-01-01},
journal = {Brain Commun},
volume = {5},
number = {6},
pages = {fcad309},
abstract = {Hippocampal atrophy is a well-known feature of age-related memory decline, and hippocampal subfields may contribute differently to this decline. In this cross-sectional study, we investigated the associations between hippocampal subfield volumes and performance in free recall and recognition memory tasks in both verbal and visual modalities in older adults without dementia. We collected MRIs from 97 (41 males) right-handed participants aged over 60. We segmented the right and left hippocampi into (i) dentate gyrus and cornu ammonis 4 (DG/CA4); (ii) CA2 and CA3 (CA2/CA3); (iii) CA1; (iv) strata radiatum, lacunosum and moleculare; and (v) subiculum. Memory was assessed with verbal free recall and recognition tasks, as well as visual free recall and recognition tasks. Amyloid-β and hippocampal tau positivity were assessed using [F]AZD4694 and [F]MK6240 PET tracers, respectively. The verbal free recall and verbal recognition performances were positively associated with CA1 and strata radiatum, lacunosum and moleculare volumes. The verbal free recall and visual free recall were positively correlated with the right DG/CA4. The visual free recall, but not verbal free recall, was also associated with the right CA2/CA3. The visual recognition was not significantly associated with any subfield volume. Hippocampal tau positivity, but not amyloid-β positivity, was associated with reduced DG/CA4, CA2/CA3 and strata radiatum, lacunosum and moleculare volumes. Our results suggest that memory performances are linked to specific subfields. CA1 appears to contribute to the verbal modality, irrespective of the free recall or recognition mode of retrieval. In contrast, DG/CA4 seems to be involved in the free recall mode, irrespective of verbal or visual modalities. These results are concordant with the view that DG/CA4 plays a primary role in encoding a stimulus' distinctive attributes, and that CA2/CA3 could be instrumental in recollecting a visual memory from one of its fragments. Overall, we show that hippocampal subfield segmentation can be useful for detecting early volume changes and improve our understanding of the hippocampal subfields' roles in memory.},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
Therriault, Joseph; Lussier, Firoza Z; Tissot, Cécile; Chamoun, Mira; Stevenson, Jenna; Rahmouni, Nesrine; Pallen, Vanessa; Bezgin, Gleb; Servaes, Stijn; Kunach, Peter; Wang, Yi-Ting; Fernandez-Arias, Jaime; Vermeiren, Marie; Pascoal, Tharick A; Massarweh, Gassan; Vitali, Paolo; Soucy, Jean-Paul; Saha-Chaudhuri, Paramita; Gauthie, Serge; Rosa-Neto, Pedro
Amyloid beta plaque accumulation with longitudinal [18F]AZD4694 PET Journal Article
In: Alzheimers Dement (Amst), vol. 15, no. 3, pp. e12391, 2023, ISSN: 2352-8729.
@article{pmid37644990,
title = {Amyloid beta plaque accumulation with longitudinal [18F]AZD4694 PET},
author = {Joseph Therriault and Firoza Z Lussier and Cécile Tissot and Mira Chamoun and Jenna Stevenson and Nesrine Rahmouni and Vanessa Pallen and Gleb Bezgin and Stijn Servaes and Peter Kunach and Yi-Ting Wang and Jaime Fernandez-Arias and Marie Vermeiren and Tharick A Pascoal and Gassan Massarweh and Paolo Vitali and Jean-Paul Soucy and Paramita Saha-Chaudhuri and Serge Gauthie and Pedro Rosa-Neto},
doi = {10.1002/dad2.12391},
issn = {2352-8729},
year = {2023},
date = {2023-01-01},
journal = {Alzheimers Dement (Amst)},
volume = {15},
number = {3},
pages = {e12391},
abstract = {INTRODUCTION: [18F]AZD4694 is an amyloid beta (Aβ) imaging agent used in several observational studies and clinical trials. However, no studies have yet published data on longitudinal Aβ accumulation measured with [18F]AZD4694.nnMETHODS: We assessed 146 individuals who were evaluated with [18F]AZD4694 at baseline and 2-year follow-up. We calculated annual rates of [18F]AZD4694 change for clinically defined and biomarker-defined groups.nnRESULTS: Cognitively unimpaired (CU) older adults displayed subtle [18F]AZD4694 standardized uptake value ratio (SUVR) accumulation over the follow-up period. In contrast, Aβ positive CU older adults displayed higher annual [18F]AZD4694 SUVR increases. [18F]AZD4694 SUVR accumulation in Aβ positive mild cognitive impairment (MCI) and dementia was modest across the neocortex.nnDISCUSSION: Larger increases in [18F]AZD4694 SUVR were observed in CU individuals who had abnormal amyloid positron emission tomography levels at baseline. [18F]AZD4694 can be used to monitor Aβ levels in therapeutic trials as well as clinical settings, particularly prior to initiating anti-amyloid therapies.},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
2022
Quispialaya, Kely Mónica; Therriault, Joseph; Aliaga, Antonio; Zimmermann, Maria; Fernandez-Arias, Jaime; Lussier, Firoza; Massarweh, Gassan; Pascoal, Tharick; Soucy, Jean-Paul; Gauthier, Serge; Jean-Claude, Bertrand; Gilfix, Brian; Vitali, Paolo; Rosa-Neto, Pedro
Discordance and Concordance Between Cerebrospinal and [F]FDG-PET Biomarkers in Assessing Atypical and Early-Onset AD Dementia Cases Journal Article
In: Neurology, vol. 99, no. 22, pp. e2428–e2436, 2022, ISSN: 1526-632X.
@article{pmid36266044,
title = {Discordance and Concordance Between Cerebrospinal and [F]FDG-PET Biomarkers in Assessing Atypical and Early-Onset AD Dementia Cases},
author = {Kely Mónica Quispialaya and Joseph Therriault and Antonio Aliaga and Maria Zimmermann and Jaime Fernandez-Arias and Firoza Lussier and Gassan Massarweh and Tharick Pascoal and Jean-Paul Soucy and Serge Gauthier and Bertrand Jean-Claude and Brian Gilfix and Paolo Vitali and Pedro Rosa-Neto},
doi = {10.1212/WNL.0000000000201198},
issn = {1526-632X},
year = {2022},
date = {2022-11-01},
journal = {Neurology},
volume = {99},
number = {22},
pages = {e2428--e2436},
abstract = {BACKGROUND AND OBJECTIVES: To assess the concordance and discordance between the core Alzheimer disease (AD) CSF biomarkers and [F]fluorodeoxyglucose (FDG)-PET patterns evaluated clinically in memory clinic patients who meet appropriate use criteria for AD biomarker investigations.nnMETHODS: We retrospectively assessed participants with atypical and/or early-onset dementia evaluated at a tertiary care memory clinic. All individuals underwent CSF evaluations for Aβ42, phosphorylated tau (P-tau181) and total tau, and brain [F]FDG-PET. [F]FDG-PET data were visually interpreted by 2 nuclear medicine experts as being consistent with AD or non-AD. CSF biomarker results were similarly grouped into AD biomarker positive/negative. Contingency tables and Kappa coefficients were used to establish the level of agreement and disagreement between CSF and [F]FDG-PET results in all individuals.nnRESULTS: One hundred thirty-six individuals had both [F]FDG-PET and lumbar puncture performed as part of the early-onset and/or atypical dementia assessments. [F]FDG-PET showed a pattern suggestive of AD in 43% of patients, while CSF biomarkers showed results consistent with AD in 57% of participants. In patients who met criteria for AD biomarker investigations, we found that [F]FDG-PET was discordant with CSF AD biomarkers in nearly 20% of cases; 12% of individuals with [F]FDG-PET scans consistent with AD had AD-negative CSF results; and 7% of individuals with [F]FDG-PET scans not consistent with AD had AD-positive CSF results, potentially suggesting atypical AD variants or less advanced neurodegeneration. [F]FDG-PET discriminated patients with an AD-positive CSF profile from patients with an AD-negative profile with a sensitivity and specificity higher than 80% (sensitivity: 81%, 95% CI = 71-88%, SP: 81%, 95% CI = 68-89%). Furthermore, [F]FDG-PET had a positive predictive value of 87% (95% CI = 78-93%) and a negative predictive value of 72% (95% CI = 60-82%).nnDISCUSSION: CSF and [F]FDG-PET disagreed in nearly 20% of the cases studied in this clinical series. While CSF Aβ42 and P-tau181 biomarkers are specific for AD, the topographical information from [F]FDG-PET may provide complementary information.},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
Therriault, Joseph; Pascoal, Tharick A; Savard, Mélissa; Mathotaarachchi, Sulantha; Benedet, Andréa L; Chamoun, Mira; Tissot, Cécile; Lussier, Firoza Z; Rahmouni, Nesrine; Stevenson, Jenna; Qureshi, Muhammad Naveed Iqbal; Kang, Min Su; Thomas, Émilie; Vitali, Paolo; Soucy, Jean-Paul; Massarweh, Gassan; Saha-Chaudhuri, Paramita; Gauthier, Serge; Rosa-Neto, Pedro
Intrinsic connectivity of the human brain provides scaffold for tau aggregation in clinical variants of Alzheimer's disease Journal Article
In: Sci Transl Med, vol. 14, no. 659, pp. eabc8693, 2022, ISSN: 1946-6242.
@article{pmid36001678,
title = {Intrinsic connectivity of the human brain provides scaffold for tau aggregation in clinical variants of Alzheimer's disease},
author = {Joseph Therriault and Tharick A Pascoal and Mélissa Savard and Sulantha Mathotaarachchi and Andréa L Benedet and Mira Chamoun and Cécile Tissot and Firoza Z Lussier and Nesrine Rahmouni and Jenna Stevenson and Muhammad Naveed Iqbal Qureshi and Min Su Kang and Émilie Thomas and Paolo Vitali and Jean-Paul Soucy and Gassan Massarweh and Paramita Saha-Chaudhuri and Serge Gauthier and Pedro Rosa-Neto},
doi = {10.1126/scitranslmed.abc8693},
issn = {1946-6242},
year = {2022},
date = {2022-08-01},
journal = {Sci Transl Med},
volume = {14},
number = {659},
pages = {eabc8693},
abstract = {Alzheimer's disease (AD) phenotypes might result from differences in selective vulnerability. Evidence from preclinical models suggests that tau pathology has cell-to-cell propagation properties. Therefore, here, we tested the cell-to-cell propagation framework in the amnestic, visuospatial, language, and behavioral/dysexecutive phenotypes of AD. We report that each AD phenotype is associated with a distinct network-specific pattern of tau aggregation, where tau aggregation is concentrated in brain network hubs. In all AD phenotypes, regional tau load could be predicted by connectivity patterns of the human brain. Furthermore, regions with greater connectivity displayed similar rates of longitudinal tau accumulation in an independent cohort. Connectivity-based tau deposition was not restricted to a specific vulnerable network but was rather a general property of brain organization, linking selective vulnerability and transneuronal spreading models of neurodegeneration. Together, this study indicates that intrinsic brain connectivity provides a framework for tau aggregation across diverse phenotypic manifestations of AD.},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
Therriault, Joseph; Pascoal, Tharick A; Lussier, Firoza Z; Tissot, Cécile; Chamoun, Mira; Bezgin, Gleb; Servaes, Stijn; Benedet, Andrea L; Ashton, Nicholas J; Karikari, Thomas K; Lantero-Rodriguez, Juan; Kunach, Peter; Wang, Yi-Ting; Fernandez-Arias, Jaime; Massarweh, Gassan; Vitali, Paolo; Soucy, Jean-Paul; Saha-Chaudhuri, Paramita; Blennow, Kaj; Zetterberg, Henrik; Gauthier, Serge; Rosa-Neto, Pedro
Biomarker modeling of Alzheimer's disease using PET-based Braak staging Journal Article
In: Nat Aging, vol. 2, no. 6, pp. 526–535, 2022, ISSN: 2662-8465.
@article{pmid37118445,
title = {Biomarker modeling of Alzheimer's disease using PET-based Braak staging},
author = {Joseph Therriault and Tharick A Pascoal and Firoza Z Lussier and Cécile Tissot and Mira Chamoun and Gleb Bezgin and Stijn Servaes and Andrea L Benedet and Nicholas J Ashton and Thomas K Karikari and Juan Lantero-Rodriguez and Peter Kunach and Yi-Ting Wang and Jaime Fernandez-Arias and Gassan Massarweh and Paolo Vitali and Jean-Paul Soucy and Paramita Saha-Chaudhuri and Kaj Blennow and Henrik Zetterberg and Serge Gauthier and Pedro Rosa-Neto},
doi = {10.1038/s43587-022-00204-0},
issn = {2662-8465},
year = {2022},
date = {2022-06-01},
journal = {Nat Aging},
volume = {2},
number = {6},
pages = {526--535},
abstract = {Gold-standard diagnosis of Alzheimer's disease (AD) relies on histopathological staging systems. Using the topographical information from [F]MK6240 tau positron-emission tomography (PET), we applied the Braak tau staging system to 324 living individuals. We used PET-based Braak stage to model the trajectories of amyloid-β, phosphorylated tau (pTau) in cerebrospinal fluid (pTau, pTau, pTau and pTau) and plasma (pTau and pTau), neurodegeneration and cognitive symptoms. We identified nonlinear AD biomarker trajectories corresponding to the spatial extent of tau-PET, with modest biomarker changes detectable by Braak stage II and significant changes occurring at stages III-IV, followed by plateaus. Early Braak stages were associated with isolated memory impairment, whereas Braak stages V-VI were incompatible with normal cognition. In 159 individuals with follow-up tau-PET, progression beyond stage III took place uniquely in the presence of amyloid-β positivity. Our findings support PET-based Braak staging as a framework to model the natural history of AD and monitor AD severity in living humans.},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
Savard, Melissa; Pascoal, Tharick A; Servaes, Stijn; Dhollander, Thijs; Iturria-Medina, Yasser; Kang, Min Su; Vitali, Paolo; Therriault, Joseph; Mathotaarachchi, Sulantha; Benedet, Andrea Lessa; Gauthier, Serge; and, Pedro Rosa-Neto
Impact of long- and short-range fibre depletion on the cognitive deficits of fronto-temporal dementia Journal Article
In: Elife, vol. 11, 2022, ISSN: 2050-084X.
@article{pmid35073256,
title = {Impact of long- and short-range fibre depletion on the cognitive deficits of fronto-temporal dementia},
author = {Melissa Savard and Tharick A Pascoal and Stijn Servaes and Thijs Dhollander and Yasser Iturria-Medina and Min Su Kang and Paolo Vitali and Joseph Therriault and Sulantha Mathotaarachchi and Andrea Lessa Benedet and Serge Gauthier and Pedro Rosa-Neto and },
doi = {10.7554/eLife.73510},
issn = {2050-084X},
year = {2022},
date = {2022-01-01},
journal = {Elife},
volume = {11},
abstract = {Recent studies suggest a framework where white-matter (WM) atrophy plays an important role in fronto-temporal dementia (FTD) pathophysiology. However, these studies often overlook the fact that WM tracts bridging different brain regions may have different vulnerabilities to the disease and the relative contribution of grey-matter (GM) atrophy to this WM model, resulting in a less comprehensive understanding of the relationship between clinical symptoms and pathology. Using a common factor analysis to extract a semantic and an executive factor, we aimed to test the relative contribution of WM and GM of specific tracts in predicting cognition in the Frontotemporal Lobar Degeneration Neuroimaging Initiative (FTLDNI). We found that semantic symptoms were mainly dependent on short-range WM fibre disruption, while damage to long-range WM fibres was preferentially associated to executive dysfunction with the GM contribution to cognition being predominant for local processing. These results support the importance of the disruption of specific WM tracts to the core cognitive symptoms associated with FTD. As large-scale WM tracts, which are particularly vulnerable to vascular disease, were highly associated with executive dysfunction, our findings highlight the importance of controlling for risk factors associated with deep WM disease, such as vascular risk factors, in patients with FTD in order not to potentiate underlying executive dysfunction.},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
2021
Therriault, Joseph; Pascoal, Tharick A; Benedet, Andrea L; Tissot, Cecile; Savard, Melissa; Chamoun, Mira; Lussier, Firoza; Kang, Min Su; Berzgin, Gleb; Wang, Tina; Fernandes-Arias, Jaime; Massarweh, Gassan; Soucy, Jean-Paul; Vitali, Paolo; Saha-Chaudhuri, Paramita; Gauthier, Serge; Rosa-Neto, Pedro
Frequency of Biologically Defined Alzheimer Disease in Relation to Age, Sex, ε4, and Cognitive Impairment Journal Article
In: Neurology, vol. 96, no. 7, pp. e975–e985, 2021, ISSN: 1526-632X.
@article{pmid33443136,
title = {Frequency of Biologically Defined Alzheimer Disease in Relation to Age, Sex, ε4, and Cognitive Impairment},
author = {Joseph Therriault and Tharick A Pascoal and Andrea L Benedet and Cecile Tissot and Melissa Savard and Mira Chamoun and Firoza Lussier and Min Su Kang and Gleb Berzgin and Tina Wang and Jaime Fernandes-Arias and Gassan Massarweh and Jean-Paul Soucy and Paolo Vitali and Paramita Saha-Chaudhuri and Serge Gauthier and Pedro Rosa-Neto},
doi = {10.1212/WNL.0000000000011416},
issn = {1526-632X},
year = {2021},
date = {2021-02-01},
journal = {Neurology},
volume = {96},
number = {7},
pages = {e975--e985},
abstract = {OBJECTIVE: To assess the frequency of biologically defined Alzheimer disease (AD) in relation to age, sex, ε4, and clinical diagnosis in a prospective cohort study evaluated with amyloid-PET and tau-PET.nnMETHODS: We assessed cognitively unimpaired (CU) elderly (n = 166), patients with amnestic mild cognitive impairment (n = 77), and patients with probable AD dementia (n = 62) who underwent evaluation by dementia specialists and neuropsychologists in addition to amyloid-PET with [F]AZD4694 and tau-PET with [F]MK6240. Individuals were grouped according to their AD biomarker profile. Positive predictive value for biologically defined AD was assessed in relation to clinical diagnosis. Frequency of AD biomarker profiles was assessed using logistic regressions with odds ratios (ORs) and 95% confidence intervals (CIs).nnRESULTS: The clinical diagnosis of probable AD dementia demonstrated good agreement with biologically defined AD (positive predictive value 85.2%). A total of 7.88% of CU were positive for both amyloid-PET and tau-PET. Frequency of biologically defined AD increased with age (OR 1.14; < 0.0001) and frequency of ε4 allele carriers (single ε4: OR 3.82; < 0.0001; double ε4: OR 17.55, < 0.0001).nnCONCLUSION: Whereas we observed strong, but not complete, agreement between clinically defined probable AD dementia and biomarker positivity for both β-amyloid and tau, we also observed that biologically defined AD was not rare in CU elderly. Abnormal tau-PET was almost exclusively observed in individuals with abnormal amyloid-PET. Our results highlight that even in tertiary care memory clinics, detailed evaluation by dementia specialists systematically underestimates the frequency of biologically defined AD and related entities.nnCLASSIFICATION OF EVIDENCE: This study provides Class I evidence that biologically defined AD (abnormal amyloid PET and tau PET) was observed in 85.2% of people with clinically defined AD and 7.88% of CU elderly.},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
Therriault, Joseph; Benedet, Andrea L; Pascoal, Tharick A; Savard, Melissa; Ashton, Nicholas J; Chamoun, Mira; Tissot, Cecile; Lussier, Firoza; Kang, Min Su; Bezgin, Gleb; Wang, Tina; Fernandes-Arias, Jaime; Massarweh, Gassan; Vitali, Paolo; Zetterberg, Henrik; Blennow, Kaj; Saha-Chaudhuri, Paramita; Soucy, Jean-Paul; Gauthier, Serge; Rosa-Neto, Pedro
Determining Amyloid-β Positivity Using F-AZD4694 PET Imaging Journal Article
In: J Nucl Med, vol. 62, no. 2, pp. 247–252, 2021, ISSN: 1535-5667.
@article{pmid32737243,
title = {Determining Amyloid-β Positivity Using F-AZD4694 PET Imaging},
author = {Joseph Therriault and Andrea L Benedet and Tharick A Pascoal and Melissa Savard and Nicholas J Ashton and Mira Chamoun and Cecile Tissot and Firoza Lussier and Min Su Kang and Gleb Bezgin and Tina Wang and Jaime Fernandes-Arias and Gassan Massarweh and Paolo Vitali and Henrik Zetterberg and Kaj Blennow and Paramita Saha-Chaudhuri and Jean-Paul Soucy and Serge Gauthier and Pedro Rosa-Neto},
doi = {10.2967/jnumed.120.245209},
issn = {1535-5667},
year = {2021},
date = {2021-02-01},
journal = {J Nucl Med},
volume = {62},
number = {2},
pages = {247--252},
abstract = {Amyloid-β deposition into plaques is a pathologic hallmark of Alzheimer disease appearing years before the onset of symptoms. Although cerebral amyloid-β deposition occurs on a continuum, dichotomization into positive and negative groups has advantages for diagnosis, clinical management, and population enrichment for clinical trials. F-AZD4694 (also known as F-NAV4694) is an amyloid-β imaging ligand with high affinity for amyloid-β plaques. Despite being used in multiple academic centers, no studies have assessed a quantitative cutoff for amyloid-β positivity using F-AZD4694 PET. We assessed 176 individuals [young adults ( = 22), cognitively unimpaired elderly ( = 89), and cognitively impaired ( = 65)] who underwent amyloid-β PET with F-AZD4694, lumbar puncture, structural MRI, and genotyping for F-AZD4694 values were normalized using the cerebellar gray matter as a reference region. We compared 5 methods for deriving a quantitative threshold for F-AZD4694 PET positivity: comparison with young-control SUV ratios (SUVRs), receiver-operating-characteristic (ROC) curves based on clinical classification of cognitively unimpaired elderly versus Alzheimer disease dementia, ROC curves based on visual Aβ-positive/Aβ-negative classification, gaussian mixture modeling, and comparison with cerebrospinal fluid measures of amyloid-β, specifically the Aβ/Aβ ratio. We observed good convergence among the 4 methods: ROC curves based on visual classification (optimal cut point, 1.55 SUVR), ROC curves based on clinical classification (optimal cut point, 1.56 SUVR) gaussian mixture modeling (optimal cut point, 1.55 SUVR), and comparison with cerebrospinal fluid measures of amyloid-β (optimal cut point, 1.51 SUVR). Means and 2 SDs from young controls resulted in a lower threshold (1.33 SUVR) that did not agree with the other methods and labeled most elderly individuals as Aβ-positive. Good convergence was obtained among several methods for determining an optimal cutoff for F-AZD4694 PET positivity. Despite conceptual and analytic idiosyncrasies linked with dichotomization of continuous variables, an F-AZD4694 threshold of 1.55 SUVR had reliable discriminative accuracy. Although clinical use of amyloid PET is currently by visual inspection of scans, quantitative thresholds may be helpful to arbitrate disagreement among raters or in borderline cases.},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
Therriault, Joseph; Pascoal, Tharick A; Savard, Melissa; Benedet, Andrea L; Chamoun, Mira; Tissot, Cecile; Lussier, Firoza; Kang, Min Su; Thomas, Emilie; Terada, Tatsuhiro; Rej, Soham; Massarweh, Gassan; Nasreddine, Ziad; Vitali, Paolo; Soucy, Jean-Paul; Saha-Chaudhuri, Paramita; Gauthier, Serge; Rosa-Neto, Pedro
Topographic Distribution of Amyloid-β, Tau, and Atrophy in Patients With Behavioral/Dysexecutive Alzheimer Disease Journal Article
In: Neurology, vol. 96, no. 1, pp. e81–e92, 2021, ISSN: 1526-632X.
@article{pmid33093220,
title = {Topographic Distribution of Amyloid-β, Tau, and Atrophy in Patients With Behavioral/Dysexecutive Alzheimer Disease},
author = {Joseph Therriault and Tharick A Pascoal and Melissa Savard and Andrea L Benedet and Mira Chamoun and Cecile Tissot and Firoza Lussier and Min Su Kang and Emilie Thomas and Tatsuhiro Terada and Soham Rej and Gassan Massarweh and Ziad Nasreddine and Paolo Vitali and Jean-Paul Soucy and Paramita Saha-Chaudhuri and Serge Gauthier and Pedro Rosa-Neto},
doi = {10.1212/WNL.0000000000011081},
issn = {1526-632X},
year = {2021},
date = {2021-01-01},
journal = {Neurology},
volume = {96},
number = {1},
pages = {e81--e92},
abstract = {OBJECTIVE: To determine the associations between amyloid-PET, tau-PET, and atrophy with the behavioral/dysexecutive presentation of Alzheimer disease (AD), how these differ from amnestic AD, and how they correlate to clinical symptoms.nnMETHODS: We assessed 15 patients with behavioral/dysexecutive AD recruited from a tertiary care memory clinic, all of whom had biologically defined AD. They were compared with 25 patients with disease severity- and age-matched amnestic AD and a group of 131 cognitively unimpaired (CU) elderly individuals. All participants were evaluated with amyloid-PET with [F]AZD4694, tau-PET with [F]MK6240, MRI, and neuropsychological testing.nnRESULTS: Voxelwise contrasts identified patterns of frontal cortical tau aggregation in behavioral/dysexecutive AD, with peaks in medial prefrontal, anterior cingulate, and frontal insular cortices in contrast to amnestic AD. No differences were observed in the distribution of amyloid-PET or atrophy as determined by voxel-based morphometry. Voxelwise area under the receiver operating characteristic curve analyses revealed that tau-PET uptake in the medial prefrontal, anterior cingulate, and frontal insular cortices were best able to differentiate between behavioral/dysexecutive and amnestic AD (area under the curve 0.87). Voxelwise regressions demonstrated relationships between frontal cortical tau load and degree of executive dysfunction.nnCONCLUSIONS: Our results provide evidence of frontal cortical involvement of tau pathology in behavioral/dysexecutive AD and highlight the need for consensus clinical criteria in this syndrome.},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
2020
Therriault, Joseph; Benedet, Andrea L; Pascoal, Tharick A; Mathotaarachchi, Sulantha; Chamoun, Mira; Savard, Melissa; Thomas, Emilie; Kang, Min Su; Lussier, Firoza; Tissot, Cecile; Parsons, Marlee; Qureshi, Muhammad Naveed Iqbal; Vitali, Paolo; Massarweh, Gassan; Soucy, Jean-Paul; Rej, Soham; Saha-Chaudhuri, Paramita; Gauthier, Serge; Rosa-Neto, Pedro
Association of Apolipoprotein E ε4 With Medial Temporal Tau Independent of Amyloid-β Journal Article
In: JAMA Neurol, vol. 77, no. 4, pp. 470–479, 2020, ISSN: 2168-6157.
@article{pmid31860000,
title = {Association of Apolipoprotein E ε4 With Medial Temporal Tau Independent of Amyloid-β},
author = {Joseph Therriault and Andrea L Benedet and Tharick A Pascoal and Sulantha Mathotaarachchi and Mira Chamoun and Melissa Savard and Emilie Thomas and Min Su Kang and Firoza Lussier and Cecile Tissot and Marlee Parsons and Muhammad Naveed Iqbal Qureshi and Paolo Vitali and Gassan Massarweh and Jean-Paul Soucy and Soham Rej and Paramita Saha-Chaudhuri and Serge Gauthier and Pedro Rosa-Neto},
doi = {10.1001/jamaneurol.2019.4421},
issn = {2168-6157},
year = {2020},
date = {2020-04-01},
journal = {JAMA Neurol},
volume = {77},
number = {4},
pages = {470--479},
abstract = {IMPORTANCE: Apolipoprotein E ε4 (APOEε4) is the single most important genetic risk factor for Alzheimer disease. While APOEε4 is associated with increased amyloid-β burden, its association with cerebral tau pathology has been controversial.nnOBJECTIVE: To determine whether APOEε4 is associated with medial temporal tau pathology independently of amyloid-β, sex, clinical status, and age.nnDESIGN, SETTING, AND PARTICIPANTS: This is a study of 2 cross-sectional cohorts of volunteers who were cognitively normal, had mild cognitive impairment (MCI), or had Alzheimer disease dementia: the Translational Biomarkers in Aging and Dementia (TRIAD) study (data collected between October 2017 and July 2019) and the Alzheimer's Disease Neuroimaging Initiative (ADNI) (collected between November 2015 and June 2019). The first cohort (TRIAD) comprised cognitively normal elderly participants (n = 124), participants with MCI (n = 50), and participants with Alzheimer disease (n = 50) who underwent tau positron emission tomography (PET) with fluorine 18-labeled MK6240 and amyloid-β PET with [18F]AZD4694. The second sample (ADNI) was composed of cognitively normal elderly participants (n = 157), participants with MCI (n = 83), and participants with Alzheimer disease (n = 25) who underwent tau PET with [18F]flortaucipir and amyloid-β PET with [18F]florbetapir. Exclusion criteria were a history of other neurological disorders, stroke, or head trauma. There were 489 eligible participants, selected based on availability of amyloid-PET, tau-PET, magnetic resonance imaging, and genotyping for APOEε4. Forty-five young adults (<30 years) from the TRIAD cohort were not selected for this study.nnMAIN OUTCOMES AND MEASURES: A main association between APOEε4 and tau-PET standardized uptake value ratio, correcting for age, sex, clinical status, and neocortical amyloid-PET standardized uptake value ratio.nnRESULTS: The mean (SD) age of the 489 participants was 70.5 (7.1) years; 171 were APOEε4 carriers (34.9%), and 230 of 489 were men. In both cohorts, APOEε4 was associated in increased tau-PET uptake in the entorhinal cortex and hippocampus independently of amyloid-β, sex, age, and clinical status after multiple comparisons correction (TRIAD: β = 0.33; 95% CI, 0.19-0.49; ADNI: β = 0.13; 95% CI, 0.08-0.19; P < .001).nnCONCLUSIONS AND RELEVANCE: Our results indicate that the elevated risk of developing dementia conferred by APOEε4 genotype involves mechanisms associated with both amyloid-β and tau aggregation. These results contribute to an evolving framework in which APOEε4 has deleterious consequences in Alzheimer disease beyond its link with amyloid-β and suggest APOEε4 as a potential target for future disease-modifying therapeutic trials targeting tau pathology.},
keywords = {},
pubstate = {published},
tppubtype = {article}
}